🍪 Our Cookies

This website uses cookies, pixel tags, and similar technologies (“Cookies”) for the purpose of enabling site operations and for performance, personalisation, and marketing purposes. We use our own Cookies and some from third parties. Only essential Cookies are used by default. By clicking “Accept All” you consent to the use of non-essential Cookies (i.e., functional, analytics, and marketing Cookies) and the related processing of personal data. You can manage your consent preferences by clicking Manage Preferences. You may withdraw a consent at any time by using the link “Cookie Preferences” in the footer of our website.

Our Privacy Notice is accessible here. To learn more about the use of Cookies on our website, please view our Cookie Notice.

Share

Market Wrap

Taking the Credit — Buy-and-build, investment grade offer, and much bother over interest cover

Josie Shillito's avatar
  1. Josie Shillito
4 min read

Private credit’s ardour for the healthcare, IT and financial services sectors shows no sign of dimming as we straddle the boundary between H1 and H2. Not only are these businesses generative in recurring revenue, but they require flexible pools of capital to pursue their acquisitive strategies: the type only private credit can provide.

At least two €1bn plus private credit deals are floating about the market ahead of summer: a dual-track process (banks and private credit funds) on the acquisition financing of the buy-and-build heavy, Triton-owned UK specialty pharma business Pharmanovia, and a €1bn refinancing of Astorg-owned investor services business IQ-EQ, also an acquisitive business

Read all our public content for free

We won't spam. You can unsubscribe at any time.

What are you waiting for?

Try it out
  • We're trusted by the top 10 Investment Banks